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Abstract 
Surgical resection remains the major modality for modern curative treatment for solid tumours. 
However, post-surgical recurrence, even following clear-margin resection and adjuvant treatment, 
remains common in many types of cancer. Reducing recurrence rates, therefore, offers the potential 
to increase cure rates and increase overall survival. Perioperative therapies, simple interventions 
during the perioperative period, are designed to address some of the factors which influence post-
surgical recurrence.  A range of perioperative therapies are introduced and the rationale for further 
clinical investigation outlined. 
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Introduction 
Even with the promise of precision medicine and onco-immunotherapy, surgical resection remains 
the major modality for modern curative treatment for solid tumours. For many types of cancer clear-
margin (R0) resection represents the best chance for patients to achieve long-term survival. It 
remains true that despite recent significant advances, for example in immuno-oncology, metastatic 
cancers are difficult to treat and long-term survival poor. In all too many cases, even curative 
resection with clear margins is a prelude to disease recurrence, even when surgery is followed by 
adjuvant treatment.  
The phenomenon of post-surgical distant recurrence is common in a number of cancers, including 
breast, non-small cell lung cancer, osteosarcoma and others (Table 1). In osteosarcoma, for example, 
a disease in which there have been no significant improvements in overall survival for more than 30 
years, local recurrence post-surgery occurs in 6% of cases, compared to a distant recurrence rate of 
47% 
1
. Across a broad range of solid tumours the pattern of early distant recurrence following 
surgical resection is remarkably consistent and yet there has been little sustained effort to address 
the issue. Definitive R0 surgical resections and the reduction of recurrence rates, therefore, hold the 
potential to significantly improve overall survival by increasing cure rates. A range of interventions in 
the perioperative period, which we term perioperative therapies, may be a means to this end. 
In contrast, there has been a concerted effort to develop systemic therapies to address the unmet 
needs associated with metastatic disease. Molecularly targeted drugs, onco-immunotherapies, 
proton beam radiation and other high-cost interventions have been a particular focus for 
development, driven by commercial as well as patient agendas. Results to date have been mixed, 
and the impact on overall population survival has, on the whole, been very modest.  
There is also increasing concern about the long-term economic burdens associated with these high-
cost interventions. Such concerns, driven both by the rising prices and costs of new drugs and 
technologies and by the projected increases in cancer incidence, are common to both high income 
and to low and middle income countries alike. In the absence of significant price reduction strategies 
these new treatments are likely to impose even more significant strains on stressed health systems 
in high income countries, and to rule out such treatments in low and middle income countries for 
many years to come. In this context it becomes imperative to explore other strategies to achieve 
substantial clinical benefit but with a cost profile that imposes a lower level of financial stress on 
health systems. 
Perioperative intervention to reduce the risk of post-surgical recurrence is one such strategy. In 
contrast to neoadjuvant therapies, which are primarily intended to downstage tumours to facilitate 
successful resection, perioperative therapies are designed to decrease the risk of disease recurrence 
after successful resection. We should note that even when patients achieve pathological complete 
response (pCR) following neoadjuvant therapy there remains a risk of relapse, for example in breast 
cancer there is a 15% risk of relapse (local or distant) after achieving pCR. The need, therefore, for 
perioperative therapies exists even in those cancers in which neoadjuvant therapies are established 
as the standard of care. 
Factors Influencing Post-surgical Recurrence 
There are multiple mechanisms associated with post-surgical recurrence, as shown in Figure 1, 
primarily associated with the inflammatory wound-healing response that follows surgical incision. 
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This wound-healing response initiates a cascade of pro-angiogenic signalling, the upregulation of 
catecholamines and pro-metastatic prostaglandins and the onset of cell-mediated 
immunosuppression.  
Other factors include psychological distress, the impact of analgesics and anaesthesia, surgical 
hypothermia, hypoxia, surgically-induced increased lysyl oxidase (LOX) activity, tissue damage and 
the release of cancer cells into the circulation. A number of reviews have outlined these and other 
relevant mechanisms in some detail, drawing particularly on data from animal models of post-
surgical relapse 
2
. We should note that while poor surgical technique and lack of expertise also have 
an impact on outcomes, the mechanisms described in Figure 1 occur even after skilfully executed 
clear-margin tumour resection. We may speculate that the gains from improvements in surgical 
expertise and from the adoption of perioperative therapies are likely to be additive. 
 
Perioperative Therapies 
This knowledge of the mechanisms opens the door to a range of interventions which target relevant 
pathways such that one or more of these pro-metastatic pathways is inhibited, thereby reducing the 
risk of loco-regional recurrence or metastatic spread. Significantly, a number of such interventions 
are supported by evidence of efficacy in clinical trials (Table 2). For instance, a Phase III trial of 
preoperative depot progesterone, in women under-going mastectomy, showed disease-free survival 
and overall survival were improved in node-positive women 
3
.  
There are also mechanistic reasons to support the use of other agents in the perioperative period, 
for example the use of tranexamic acid to reduce intra-operative blood loss in liver cancer surgery 
which is known to increase the risk of recurrence (which may due to increased tumour shedding or 
the impact of peripheral blood transfusion).  Additionally there are a number of non-
pharmacological perioperative interventions which may also be efficacious in reducing distant 
recurrence, including regional anaesthesia and enhanced recovery programs initiated before 
surgery, which includes nutritional support, physical training and stress management.  
These various interventions have a number of features in common, in addition to the existing pre-
clinical and clinical evidence in their favour. The first is that these are generally interventions of short 
duration, in the case of ketorolac and depot progesterone a single administration prior to surgical 
incision, in the other cases the interventions are of one or two weeks duration prior to and/or 
following surgery. Secondly, the agents used are low in cost –  in fact the examples cited are all 
generic and generally available for repurposing globally 
4
 . Together the low cost of the drugs and 
the short duration of treatment renders this approach affordable in all parts of the world. Indeed 
from a global perspective most patients present with locally advanced and inoperable, metastatic 
disease. The use of this intervention strategy more widely in surgical models of care has the 
potential to provide highly cost effective improvements in control and cure.  
Clinical trials of perioperative therapies require little investment in terms of drug costs or changes to 
clinical procedure or the use of new surgical techniques. However, clinical trials are costly to 
establish and administer and the use of low-cost repurposed drugs means there is little financial 
incentive for investment from the pharmaceutical industry. Furthermore such clinical trials require 
long-term follow-up of patients to assess recurrence rates and overall survival, often a challenge in 
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many countries where patients are lost to follow up. Nevertheless, where this can be overcome, the 
use of modern clinical trial designs, notably multi-arm, multi-stage trials, is particularly suitable for 
these types of interventions and can maximise the informational value and minimise the 
administrative burdens associated with clinical research. International collaborations can help focus 
on those cancers with the greatest potential for benefit and assess multiple possible interventions in 
parallel.  
Other challenges to implementation include the interdisciplinary nature of perioperative treatments 
– of necessity such trials require the close cooperation of surgeons, anaesthesiologists and medical 
oncologists. In which medical specialism do these treatments sit? It is also the case that in many 
institutions, particularly in non-academic centres, there is a paucity of surgical trial experience 
compared to medical oncology experience.  
Discussion 
Owing to the complexity of the surgical stress response, it will also be important to conduct 
biological studies to have a better understanding of the physiological processes driving local 
recurrence and metastatic spread. While immune suppression at the time of surgery is one major 
aspect to explore, other important mechanisms are also involved. Lymphatic vessel dilation or 
interaction between platelets and tumour cells are examples of additional mechanisms likely to be 
major contributors to this phenomenon. In parallel to clinical trials, gathering additional biological 
data will be of the outmost importance to learn from possible failures and to build on possible 
successes. The development of surrogate markers of clinical benefit, particularly blood-borne 
biomarkers (circulating tumour cells etc), may further improve the response rates and aid in 
selecting those patients most likely to see improved outcomes from such interventions. 
In an age of precision medicine, immunotherapy and high-technology, perioperative therapies with 
off-patent generic drugs are decidedly low-tech and easy to deliver. In some cases, for example the 
pre-incisional use of ketorolac, clinical adoption following evidence of efficacy will not require 
additional licensing or market authorisation procedures and therefore adoption may proceed quickly 
and cheaply via inclusion in guidelines and updates to current practice. However, the low-cost/low-
tech model and the long duration of follow-up for studies act as disincentives to investment from 
the commercial sector, particularly the pharmaceutical industry. Given the potential benefits to 
patients, and the potential cost-effectiveness associated with these treatments, it is a matter of 
some urgency that clinical research in this area is expanded. It is clear that this research will have to 
rely mainly on public and philanthropic funds. It will also require the intellectual engagement of 
surgeons, medical oncologists and anaesthesiologists alike. This is particularly germane to low and 
middle income countries struggling with increasing cancer burdens and urgently in need of new 
affordable and efficacious treatment options that compress pathways and improve the impact on 
outcomes of current models of care.  
Recurrent and metastatic disease has immense costs to society, not just in the increased morbidity 
and mortality to affected patients, but also in the economic costs associated with additional 
treatments, lost income, family disruptions and other negative social impacts. The promise of short-
term perioperative therapy is that it enhances the chances that curative-intent surgery leads to 
definitive cure at a cost that is affordable in all economies. 
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Table 1 Patterns of recurrence after R0 resection and standard treatment in selected cancer types 
Cancer Follow-up Locoregional only Distant only Ref 
Osteosarcoma 10 year 6% 47% 
1
 
Rectal 5 year 11% 32% 
5
 
Oesophageal 5 year 21% 43% 
6
 
NSCLC 5 year 7% 13% 
7
 
Breast 10 year 8% 18% 
8
 
 
 
Table 2 Examples of pharmacological perioperative interventions with evidence supporting their role 
in preventing distant recurrence 
Interventions Cancer Type Type of evidence Results Ref 
Ketorolac Breast Human, 
retrospective 
Reduced recurrence rate (adjusted HR, 
0.37; 95% CI, 0 to 0.79, P = 0.019) 
9
 
Depot 
progesterone 
Breast Human, trial Improved DFS for node-positive 
patients (adjusted HR, 0.71; 95% CI, 
0.53 to 0.95; P = 0 .02) 
3
 
Atrial 
Natriuretic 
Peptide 
NSCLC Human, 
retrospective 
2-year RFS significantly greater in ANP-
treated patients than in control patients 
(91% vs. 75%, P = 0.018) 
10
 
Cimetidine Colorectal Human, trial Meta-analysis of five trials shows 
significant improved OS (HR, 0.53; 95% 
CI 0.32 to 0.87). 
11
 
Aspirin Rectal Human, 
retrospective 
Improved 5-year PFS (86.6% vs 67.1%; 
HR=0.20; 95% CI=0.07–0.60), OS (90.6% 
vs 73.2%; HR=0.21; 95% CI=0.05–0.89) 
and a lower metastatic risk (HR=0.30; 
95% CI=0.10–0.86). 
12
 
Arginine Head & neck Human, trial Improved OS (HR: 2.6; 95% CI: 1.1, 6.1),  
DFS (HR: 4.2; 95% CI: 1.4, 12.5) 
13
 
Calcitriol Head & neck Human, trial Increased time to recurrence 
(treatment group median 620 days, 
control 181 days, P=0.048)  
14
 
Propranolol 
+/- etodolac 
Several In vivo, human 
trials ongoing 
Significantly increased murine survival 
rates (P = 0.0315) 
15
 
IL2 Renal cell Human, trial Improved five year tumour-specific 
survival rate (86% vs 73%, P=0.043) and 
PFS rate (81% vs 62%, P=0.019). 
16
 
 
Figure 1: 
 Post-surgical recurrence following R0 resection, potential mechanisms of action 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Cancer 
Surgery
Recurrence
Angiogenesis ↑
Cell-mediated 
Immunity ↓
Tumour cell 
escape ↑
Inflammatory 
response ↑
Platelet 
mobilisaon ↑
Anaesthetics
Analgesics
Immunonutrition
Beta-blockade
Anti-
inflammatories
Perioperative
Interventions
